8-K/A: LENSAR Reports Strong Q1 2025 Revenue Growth Amidst Alcon Acquisition

LENSAR, Inc. announced a 34% increase in revenue for Q1 2025, driven by higher system sales and procedure volumes, while also reporting a significant net loss due to warrant liability changes related to its pending acquisition by Alcon.

Summary

• LENSAR reported a 34% increase in total revenue for the quarter ended March 31, 2025, reaching $14.2 million compared to $10.6 million in the same period of 2024.
• The increase was primarily driven by higher system sales and increased procedure volume.
• Worldwide procedure volume increased by approximately 33% in the first quarter of 2025 compared to 2024.
• The company placed 14 ALLY Systems during the quarter, bringing the total installed base to approximately 150 ALLY Systems and a combined installed base of 395 systems.
• Recurring revenue accounted for 81% of total revenue in Q1 2025.
• Selling, general, and administrative expenses increased by $4.4 million, or 64%, primarily due to acquisition-related costs associated with the proposed merger with Alcon.
• Net loss for the quarter was $27.3 million, or ($2.32) per common share, compared to a net loss of $2.2 million, or ($0.19) per common share, for the quarter ended March 31, 2024.
• The increase in net loss was primarily due to a change in warrant liability associated with a significant appreciation in the company's stock price.
• EBITDA for the quarter was ($26.4) million, while adjusted EBITDA was $0.2 million.
• As of March 31, 2025, the company had cash, cash equivalents, and investments of $25.2 million.
• The company received a $10.0 million cash deposit in connection with the Alcon Transaction in the first quarter of 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and increased procedure volumes, but tempered by a significant net loss and the uncertainties surrounding the pending acquisition by Alcon.

Positives

• LENSAR experienced a significant increase in revenue, growing by 34% year-over-year.
• Procedure volumes increased by 33% compared to the first quarter of the previous year.
• The company successfully placed 14 ALLY Systems, expanding its installed base.
• Recurring revenue remains a strong component of the business, representing 81% of total revenue.
• Cash reserves increased to $25.2 million, bolstered by a $10 million deposit related to the Alcon acquisition.

Negatives

• The company reported a substantial net loss of $27.3 million for the quarter.
• The net loss was primarily driven by a change in warrant liability due to stock price appreciation.
• Selling, general, and administrative expenses increased significantly due to acquisition-related costs.
• EBITDA was negative at ($26.4) million.

Risks

• The proposed merger with Alcon may not be completed in a timely manner or at all.
• Required regulatory approvals may not be obtained or may be subject to unanticipated conditions.
• The failure to realize the anticipated benefits of the proposed merger.
• Competing offers or acquisition proposals for the company may be made.
• The milestone related to the contingent value rights may not be achieved.
• Legal proceedings may be instituted against the company following the announcement of the merger.
• The company's stock price may decline significantly if the merger is not consummated.

Future Outlook

The press release contains forward-looking statements regarding the proposed acquisition of the company by Alcon, the expected timing of the closing of the Alcon Transaction, and other potential future events. The company does not provide specific financial guidance beyond the reported quarter.

Management Comments

• Nick Curtis, President and CEO of LENSAR, stated, 'We had a solid start to 2025, as we successfully placed 40% more ALLY Systems in the first quarter of 2025, compared to the first quarter of 2024.'
• Nick Curtis also noted that the company achieved a substantial 34% increase in revenue and worldwide procedure volumes were 33% above first quarter 2024 levels.
• Nick Curtis mentioned that the company began to see the positive impact of the ALLY Systems placed in the latter half of 2024 as they contributed to significantly higher procedure volume and recurring revenue year over year.

Industry Context

LENSAR operates in the medical device industry, specifically focusing on advanced robotic laser solutions for cataract treatment. The announcement of the acquisition by Alcon, a major player in the eye care industry, indicates a potential consolidation trend and highlights the value of LENSAR's technology and market position.

Comparison to Industry Standards

• Comparing LENSAR's 34% revenue growth to other medical device companies in the ophthalmology sector, such as Johnson & Johnson Vision or Carl Zeiss Meditec, would provide a benchmark for assessing its performance.
• The 33% increase in worldwide procedure volumes can be compared to industry growth rates for cataract surgery to determine if LENSAR is gaining market share.
• The installed base of approximately 395 systems can be compared to competitors like Alcon's LenSx system or Johnson & Johnson's Catalys system to assess market penetration.

Legal Proceedings

• Legal proceedings may be instituted against the company following the announcement of the merger.

Stakeholder Impact

• Shareholders will be impacted by the proposed merger with Alcon and the potential payment to be made to the company's stockholders.
• Employees may be affected by the merger, including potential changes in roles and responsibilities.
• Customers (surgeons and patients) may experience changes in product offerings and support as a result of the merger.
• Suppliers and creditors may be impacted by the change in ownership and potential changes in business strategy.

Next Steps

• A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed merger.
• The company expects to file with the SEC a proxy statement and other relevant documents in connection with the proposed merger.

Key Dates

Keywords

LENSAR, ALLY Robotic Laser Cataract System, Cataract Surgery, Alcon, Merger, Revenue, Procedure Volume, Financial Results, EBITDA, Net Loss